An Introduction to Blood-Derived Cellular Therapy
Patients may undergo a blood-derived cellular therapy. This purely blood-derived therapeutic option is less invasive. The blood-derived cellular therapy has proven effective in combating chronic lung disease. For optimal results, follow-up therapies may need to be performed more often.
How Blood-Derived Cellular Therapy Works
The blood-derived procedure is performed in a clinical outpatient setting over the course of three days. After the Lung Institute’s medical staff has determined that a patient is a candidate for blood-derived cellular therapy, he or she will be asked to fill out all of the required paperwork and necessary forms. An electrocardiogram (EKG) and pulmonary function test will be performed, and the patient will go through a preparation process to stimulate stem cell production within the body. Following the insertion of an IV, the autologous hematopoietic cells are harvested, washed, isolated and returned to the patient’s body intravenously where they can begin restoring the patient’s lungs. This process is repeated on days two and three of the patient’s therapy program. This minimally invasive procedure has proven to be a viable option for many patients with chronic obstructive pulmonary disease (COPD). At the end of day three, the overseeing physician will do a thorough final evaluation of the patient’s cellular therapy and prep him or her for follow-up care.
Blood-derived Cellular Therapy Follow-Up Care
The patient will receive follow up care two weeks, three months and six months following his or her therapy. The patient is encouraged to return for a follow-up appointment with his or her pulmonologist at the three-month mark.